Jason C. Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, Clinical Professor and Director of the Postgraduate Year Two Infectious Diseases Residency at the Temple University School of Pharmacy and Clinical Pharmacist Specialist in Infectious Diseases at Temple University Hospital, spoke with Verywell Health about the U.S. Food and Drug Administration (FDA)’s decision to revoke emergency use authorization for the last remaining monoclonal antibody treatment for COVID-19.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH